Characterizing the cross-sectional approach to investigate the prevalence of tissue BRCA1/2 mutations in newly diagnosed advanced ovarian cancer patients
Not Applicable
- Conditions
- Patients with newly diagnosed (at the first diagnosis of) FIGO stage III - IV ovarian cancer (OC)
- Registration Number
- JPRN-UMIN000039226
- Lead Sponsor
- AstraZeneca K.K.
- Brief Summary
This study was conducted in 20 study sites in Japan and included patients with newly diagnosed OC of FIGO stage III and IV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 206
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who are not recommended enrolling this study decided by study investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method